Ketamine Therapy vs. TMS for Depression

Most pages comparing ketamine therapy and TMS (transcranial magnetic stimulation) are published by a clinic that offers one of the two, and they read that way — every comparison tilts toward whatever the clinic sells. This page doesn't sell either treatment. Both are legitimate, FDA-recognized options for depression that hasn't responded to standard antidepressants, and they work through different mechanisms, on different schedules, with different insurance realities. Which one fits a given patient depends on documented treatment history, logistics, and tolerance for the procedure itself — a decision made with a psychiatric provider, not by reading a comparison page.

How Ketamine Therapy Works

Ketamine is a dissociative anesthetic that, at the sub-anesthetic doses used for depression, blocks NMDA glutamate receptors in the brain. That blockade sets off synaptic changes — often described as encouraging new connections between neurons — that can ease depressive symptoms through a different pathway than SSRIs or SNRIs use. Clinics deliver it several ways: an IV ketamine infusion gives a precise, weight-based dose through an intravenous line over 40 to 60 minutes; IM (intramuscular) injection is a simpler alternative; Spravato (esketamine) is a nasal spray version of one molecule in ketamine, self-administered under supervision; and some telehealth programs prescribe oral ketamine troches for at-home use under less direct oversight. Whatever the format, the patient is briefly dissociated — perception, sense of time, and body awareness shift for the duration of the dose — which is why every ketamine session requires a monitored recovery period before discharge.

How TMS Works

TMS uses a magnetic coil placed against the scalp to deliver rapid pulses that stimulate the dorsolateral prefrontal cortex, a brain region tied to mood regulation that tends to be underactive in depression. Unlike ketamine, TMS puts no drug into the bloodstream and involves no sedation and no dissociation — patients sit in a chair, stay fully alert, and can drive themselves home or return to work right after. The sensation is a tapping or knocking feeling on the scalp along with the coil's clicking sound; some patients find the first few sessions uncomfortable before adjusting, and clinics adjust the pulse intensity accordingly. Because no systemic medication is involved, TMS avoids the drug-interaction and organ-function screening that comes up when evaluating candidates for ketamine — though it brings its own screening questions, mainly around metal implants near the head and seizure history.

FDA Status and Approved Uses

The two sit in different regulatory categories, which matters for both safety oversight and insurance. TMS is FDA-cleared as a medical device for major depressive disorder (since 2008) and for obsessive-compulsive disorder — device clearance is a different pathway than drug approval, but it still requires evidence of safety and effectiveness for the cleared use. Spravato (esketamine) is FDA-approved as a drug specifically for treatment-resistant depression and for depressive symptoms in adults with suicidal thoughts, used alongside an oral antidepressant. Generic IV and IM ketamine, by contrast, has no FDA approval for any mental health use — it's approved only as a surgical anesthetic, and its use for depression, anxiety, or pain is entirely off-label, prescribed at a physician's discretion based on published clinical literature. Off-label doesn't mean unproven or unsafe, but it explains much of the gap in how insurers treat the two, covered below.

What the Evidence Base Looks Like

Both treatments have been studied in randomized, controlled trials for depression, but the evidence sits in different places. TMS has the longer track record: it went through the FDA device-clearance process, has been published in peer-reviewed sham-controlled trials, and has been used clinically since 2008, so its evidence base is broader and more established. Ketamine's research use for depression goes back to the 1990s and 2000s, well ahead of Spravato's 2019 approval, and most of what's published on generic IV/IM ketamine is investigator-initiated academic research rather than the pharmaceutical-sponsored trials that support an FDA drug approval — part of why it remains off-label despite a substantial body of published studies. Neither point should read as one treatment being unproven; it reflects how differently a medical device, a newly approved drug, and an older generic drug used off-label move through the regulatory and publication system. Ask a prospective clinic what published data supports the specific protocol they use and how it applies to your situation, rather than relying on response-rate claims in marketing material.

Ketamine vs. TMS at a Glance

The practical differences patients weigh most, side by side:

Session Schedule and Time Commitment

The two treatments ask very different things of your calendar. A standard TMS course is 5 sessions a week for about 6 weeks — 30 or more individual visits, each roughly 20 to 40 minutes, not counting travel time. That's a substantial commitment for anyone working a standard job, though many clinics offer early-morning or lunch-hour slots specifically because patients need to return to normal activities right after. Ketamine 's induction series is shorter in visit count but each visit takes longer: a typical IV series is 6 infusions over 2 to 3 weeks, and Spravato is dosed twice weekly for the first month before tapering to weekly or biweekly maintenance. But because ketamine requires monitored recovery — 30 minutes to 2 hours depending on the format — and a driver to get home, each ketamine appointment consumes more of the surrounding day than its session length suggests, and it can't be scheduled around a lunch break the way TMS often can.

How Quickly Each Can Help

Timelines differ in a way that matters for patients in real distress. Ketamine's dissociative and mood effects begin during the session itself, and some patients notice a shift in depressive symptoms within the first one to three sessions of an induction series, part of why it's sometimes considered when a faster response is needed. TMS effects tend to build more gradually across the multi-week course; most protocols don't expect the full benefit until well into treatment, sometimes not until the final couple of weeks. Neither treatment guarantees a response, and how quickly, or whether, a given patient improves isn't something either modality can promise in advance — response varies enough between individuals that a prescribing clinician's assessment matters more than a general timeline.

Insurance and Cost Differences

This is often the deciding factor in practice. TMS has been on the market long enough, and its FDA clearance is broad enough, that most commercial insurers and Medicare cover it for patients who meet documented criteria — typically having tried and not responded to a specific number of antidepressant medications — though prior authorization and that documentation are usually required first. Spravato follows a similar path: because it's FDA-approved for treatment-resistant depression, it's frequently covered with prior authorization, and patients often pay a specialist copay rather than the full cost. Generic IV and IM ketamine sits outside that system — because the use is off-label, most insurance plans don't cover the treatment itself, so patients typically self-pay, though some clinics provide superbills for out-of-network reimbursement attempts. For a fuller breakdown of what each option tends to cost out of pocket, see how much ketamine therapy costs; for the coverage question across every ketamine format specifically, see does insurance cover ketamine therapy.

Side Effects and Safety Considerations

Ketamine's most common side effects happen during the session itself: dissociation, drowsiness, nausea, and a temporary rise in blood pressure, part of why clinics monitor vital signs throughout dosing. Less common but documented with frequent, higher-dose use are urinary and bladder symptoms; clinics screen for cardiac history and current blood pressure control before treatment, and ketamine is generally avoided in patients with a personal or family history of psychosis. TMS side effects are concentrated at the treatment site — mild scalp discomfort or headache during and shortly after sessions, usually easing over the first week or two — and don't involve dissociation, sedation, or blood-pressure changes. Its most serious rare risk is seizure, which is why TMS is contraindicated for patients with a seizure disorder or certain metal implants or devices near the head, such as some pacemakers. Reviewing personal and family medical history with a prescriber, not a general comparison like this one, is how these risks actually get screened for a specific patient.

Decision Factors, Not a Recommendation

Neither treatment is categorically better — they suit different situations. A few factors that tend to shift the decision in practice:

• Insurance coverage and documented treatment history:TMS's broader coverage often makes it the lower-cost starting point for patients who meet its documented criteria and have time for near-daily visits.
• Time and transportation:patients who can't commit to 5 visits a week for 6 weeks, or who can't easily arrange a driver, may find one modality more workable than the other for reasons that have nothing to do with clinical effectiveness.
• Speed:patients in more urgent distress sometimes prioritize ketamine's faster onset, in consultation with their care team.
• Medical history: a seizure disorder points away from TMS; a history of psychosis, uncontrolled hypertension, or substance-use concerns around ketamine points a clinician toward TMS or closer screening.
• Comfort with the procedure itself: some patients are more averse to an IV line or a nasal spray with dissociative effects, while others find sitting still for a magnetic coil session, day after day, harder to tolerate.
• Prior treatment:patients who've already tried one without adequate response are often candidates for the other, or for combining approaches.

None of these factors is decisive alone, and a psychiatric provider who knows your antidepressant history, medical history, and current symptom severity is who actually weighs them.

Can You Do Both?

Yes — the two aren't mutually exclusive, and clinicians sometimes sequence or combine them. A common pattern is trying one modality and, if the response is partial or short-lived, adding or switching to the other; some patients maintain gains from TMS with periodic ketamine boosters, or the reverse. There isn't a standardized protocol for combining them, so this is a decision to work through with a psychiatric provider familiar with both treatments — ideally one who can access records from whichever treatment you tried first, rather than starting over at an unrelated clinic.

If you've weighed the factors above and ketamine looks like the direction worth exploring, the next decision is which ketamine format — IV, injection, and Spravato differ enough to be worth comparing directly; see IV ketamine vs. Spravato: what's the difference for that breakdown. If TMS looks like the direction, the next step is finding a TMS provider — most ketamine clinics don't offer it, since it's a distinct specialty, and this directory focuses on ketamine-specific clinics, browsable by state and treatment type.

Frequently Asked Questions

Informational only — not medical advice. Discuss treatment selection with a licensed psychiatric provider who knows your treatment history.